Adenomyosis Treatment Market - Size, Share, Industry Trends, and Forecasts (2024 - 2031)

By Type:

Based on type, the market is categorized into diffuse and focal.

The diffuse segment accounted for the largest share in 2023.

• Diffuse adenomyosis refers to a condition where the endometrial tissue is evenly spread throughout the uterine wall. This type of adenomyosis leads to a more widespread thickening of the uterine walls. This results in symptoms such as heavy menstrual bleeding, pelvic pain, and sometimes infertility.
• Treatment for diffuse adenomyosis aims to manage symptoms and improve quality of life. Hormonal therapies help reduce bleeding and pain by controlling hormone levels. Nonsteroidal anti-inflammatory drugs (NSAIDs) help alleviate pain and inflammation. For more severe cases, surgical options such as hysterectomy are considered, especially if other treatments are ineffective.
• The benefits of treatment for diffuse adenomyosis include reduced symptoms, improved fertility prospects, and better overall management of the condition. This enables women to maintain a better quality of life.
• As per the analysis, the rising aging population is driving the segment, as particularly postmenopausal women are at increased risk of developing diffuse adenomyosis, requiring effective treatment for its management.
• For instance, according to the Mayo Clinic, the majority of adenomyosis cases, which are influenced by estrogen, are predominantly observed in females during their fourth and fifth decades of life.
• Overall, the rising prevalence of diffuse adenomyosis, particularly among postmenopausal women, is driving the segment in the adenomyosis treatment market growth.

The focal segment is expected to grow at the fastest CAGR over the forecast period.

• Focal adenomyosis is a localized form of adenomyosis where endometrial tissue grows within a specific area of the uterine muscle, creating a nodule or lesion. Focal adenomyosis causes severe localized pain and is mistaken for fibroids, making accurate diagnosis essential.
• Treatments such as minimally invasive surgery (e.g., laparoscopic excision), uterine artery embolization, and hormonal therapies (e.g., GnRH agonists or progestins) offer targeted relief for focal adenomyosis. These treatments aim to reduce pain, control bleeding, and preserve fertility, a key benefit for women planning pregnancies.
• Treatments such as minimally invasive surgery (e.g., laparoscopic excision), uterine artery embolization, and hormonal therapies (e.g., GnRH agonists or progestins) offer targeted relief for focal adenomyosis. These treatments aim to reduce pain, control bleeding, and preserve fertility, a key benefit for women planning pregnancies.
• Advancements in imaging technologies, such as MRI and ultrasound, are enabling more accurate diagnosis and identification of focal lesions, creating potential for the upcoming years.

By Diagnosis Type:

The diagnosis type segment is categorized into ultrasound, MRI, and endometrial biopsy.

The ultrasound segment accounted for the largest market share of 56.15% in 2023.

• Ultrasound, particularly transvaginal ultrasound (TVUS), is a primary diagnostic tool for adenomyosis. It uses high-frequency sound waves to create images of the uterus. This helps in detecting characteristic signs such as an enlarged uterus, heterogeneous myometrium, or cystic spaces. Advanced 3D ultrasound techniques enhance diagnostic accuracy.
• Ultrasound is cost-effective, widely available, non-invasive, and poses no radiation risk. It provides real-time imaging, which helps clinicians evaluate the extent and type (focal or diffuse) of adenomyosis, which is eventually very important in guiding treatment decisions for patients.
• TVUS is also beneficial for monitoring the effectiveness of treatments such as hormonal therapy or minimally invasive procedures such as uterine artery embolization.
• The rising prevalence of adenomyosis and heightened awareness of women's reproductive health are driving the ultrasound segment.
• For instance, according to a study published in 2023 by Molecular Diversity Preservation International, significantly, 40% of women identified with endometriosis have adenomyosis. Furthermore, among women receiving assisted reproductive technologies (ARTs), adenomyosis occurs in about 20% to 25% of instances. Thus, increasing cases drive the need for effective treatments.
• Overall, the increasing prevalence of adenomyosis, coupled with the advantages of ultrasound in diagnosis and monitoring, is driving the need for ultrasound-based diagnostic services.

The MRI segment is expected to grow at the fastest CAGR over the forecast period.

• Magnetic Resonance Imaging (MRI) is a valuable diagnostic tool for adenomyosis, especially in cases where ultrasound findings are inconclusive or when more detailed information is needed.
• MRI employs strong magnetic fields and radio waves to produce detailed cross-sectional images of the uterus. This helps in identifying the thickened junctional zone and myometrial abnormalities characteristic of adenomyosis.
• MRI offers superior accuracy, particularly in complex cases or when adenomyosis coexists with other uterine conditions such as fibroids. Its high-resolution imaging allows for precise mapping of the disease. This helps healthcare professionals in planning targeted treatments, such as uterine-sparing procedures. Additionally, MRI is valuable for monitoring post-treatment outcomes and assessing residual disease.
• Advances in MRI technology have improved image quality and reduced scan time, making it a more accessible and efficient diagnostic tool. Moreover, rising awareness of its benefits and increased access to advanced MRI systems are driving its adoption globally. This creates the potential for forecasted years.

By Treatment Type:

The treatment type segment is categorized into anti-inflammatory medications, hormonal medications, and surgical treatment.

The hormonal medications segment accounted for the largest market share in 2023.

• Hormonal medications are treatments that regulate hormone levels to manage symptoms of adenomyosis, such as heavy menstrual bleeding and pelvic pain. These medications work by suppressing ovulation, reducing endometrial progression, and minimizing inflammation in the uterine wall.
• There are many types of hormonal medications. Gonadotropin-releasing hormone (GnRH) agonists induce a temporary menopausal state, reducing estrogen levels and shrinking adenomyosis-affected tissue.
• Moreover, progestin-based therapies include intrauterine devices (e.g., levonorgestrel-releasing IUDs) and oral progestins, which stabilize the endometrium and reduce bleeding and pain. Combined oral contraceptives (COCS) are also very beneficial.
• For instance, according to a study published by the www.pmc.ncbi.nlm.nih.gov, in 2023, COCS function by creating a pseudo-gestational condition, which prompts decidualization and the eventual atrophy of both the endometrium and adenomyotic lesions. This leads to amenorrhea, a decrease in menstrual volume, and alleviation from dysmenorrhea, offering advantages to individuals suffering from adenomyosis.
• Thus, the segment's growth is fueled by the increasing prevalence of adenomyosis and advancements in drug formulations. Overall, the rising prevalence of adenomyosis and the effectiveness of hormonal medications in managing symptoms are driving the segment in the market.

The surgical treatment segment is expected to grow at the fastest CAGR over the forecast period.

• Surgical treatment refers to medical procedures performed to remove or alleviate adenomyosis when other treatment options fail, or symptoms are severe. It aims to improve quality of life by addressing the root cause of the condition, such as abnormal endometrial tissue growth within the uterine wall.
• There are multiple surgical treatments available. Hysterectomy is the complete removal of the uterus which is the most definitive treatment for adenomyosis. It eliminates symptoms such as chronic pain and heavy bleeding and prevents recurrence.
• Minimally invasive techniques such as laparoscopic or uterine artery embolization reduce recovery time, scarring, and post-operative complications, making them preferred options.
• Rising awareness about definitive treatment options, coupled with advancements in surgical techniques, drives the need for surgical interventions. Moreover, the adenomyosis treatment market analysis shows that the growing prevalence of severe adenomyosis cases and the limitations of hormonal and anti-inflammatory medications in managing advanced disease contribute to the growth. Increased availability of skilled surgeons and better healthcare infrastructure further boost the adoption of surgical treatments globally, creating the potential for the upcoming years.

By End-User:

The end-user segment is categorized into hospitals, clinics, and ambulatory surgical centers.

Trends in the end-user:

• Growing adoption of advanced diagnostic and treatment technologies.
• Growing popularity for outpatient procedures such as uterine artery embolization (UAE)

The hospitals and clinics segment accounted for the largest market share in 2023.

• Hospitals are large healthcare institutions equipped with advanced medical infrastructure, multidisciplinary teams, and comprehensive facilities to provide diagnosis, treatment, and post-operative care for various medical conditions, including adenomyosis.
• They serve as primary treatment centers for complex and severe cases requiring specialized interventions.
• Hospitals dominate the adenomyosis treatment segment due to their superior diagnostic and therapeutic capabilities. They house advanced imaging systems such as MRI and skilled gynecological specialists essential for accurate diagnosis and effective treatment planning.
• Hospitals dominate the adenomyosis treatment segment due to their superior diagnostic and therapeutic capabilities. They house advanced imaging systems such as MRI and skilled gynecological specialists essential for accurate diagnosis and effective treatment planning.
• Their dominance is further driven by the high influx of patients due to referral systems, insurance coverage, and the trust associated with hospital-based treatments. The development of healthcare infrastructure, especially in emerging economies, also boosts the requirement.
• For instance, in 2023, the reported www.ceicdata.com reached 38,400 units. This marks a rise from the earlier figure of 36,976 units recorded in 2022. Thus, this has led to an increase in more diagnostic and treatment-providing facilities, positively impacting the market.
• Overall, As the prevalence of adenomyosis increases, hospitals are the preferred choice for managing severe cases, offering both expertise and convenience.

The ambulatory surgical centers segment is expected to grow at the fastest CAGR over the forecast period.

• Ambulatory surgical centers (ASCS) are healthcare facilities that provide surgical and diagnostic services on an outpatient basis, meaning patients do not require an overnight hospital stay.
• ASCs offer a cost-effective alternative to traditional hospital settings, reducing patient out-of-pocket expenses.
• Patients increasingly prefer the convenience and shorter recovery times associated with outpatient surgery. Additionally, ASCs offer shorter wait times, lower infection risks, and more personalized care, driving patient preference.
• Advances in minimally invasive surgical techniques, such as uterine artery embolization, align well with the capabilities of ASCs, reducing recovery time and costs, are driving their demand in the market.
• Moreover, healthcare policies encouraging outpatient care, coupled with rising awareness of these centers' benefits, further contribute to the growth.